Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Moodys
Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

BRIVIACT Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Briviact, and what generic alternatives are available?

Briviact is a drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this drug.

This drug has one hundred and forty-five patent family members in forty-one countries.

The generic ingredient in BRIVIACT is brivaracetam. One supplier is listed for this compound. Additional details are available on the brivaracetam profile page.

US ANDA Litigation and Generic Entry Outlook for Briviact

Briviact will be eligible for patent challenges on May 12, 2020. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 12, 2021. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for BRIVIACT
Drug patent expirations by year for BRIVIACT
Drug Prices for BRIVIACT

See drug prices for BRIVIACT

Generic Entry Opportunity Date for BRIVIACT
Generic Entry Dates for BRIVIACT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
SOLUTION;INTRAVENOUS
Generic Entry Dates for BRIVIACT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
SOLUTION;ORAL
Generic Entry Dates for BRIVIACT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRIVIACT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
UCB Biopharma S.P.R.L.Phase 3
UCB Biopharma S.P.R.L.Phase 2

See all BRIVIACT clinical trials

Pharmacology for BRIVIACT
Mechanism of ActionEpoxide Hydrolase Inhibitors
Synonyms for BRIVIACT
(2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide
(2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide
(2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butanamide
(2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
2(s)-[2-oxo-4(r)-propylpyrrolidin-1-yl]butyramide
357336-20-0
AC-29289
ACN-055569
AKOS027324306
AN-16688
AS-35277
BDBM50422531
Brivaracetam
Brivaracetam (USAN/INN)
Brivaracetam [USAN:INN]
Briviact (TN)
CHEBI:133013
CHEMBL607400
compound 83alpha
CS-3418
D08879
DB05541
EX-A2748
FT-0700965
GTPL9041
HY-14449
MSYKRHVOOPPJKU-BDAKNGLRSA-N
Rikelta
SB17229
SCHEMBL122081
U863JGG2IA
UCB 34714
UCB-34714
UCB34714
UNII-U863JGG2IA
ZINC3979899

US Patents and Regulatory Information for BRIVIACT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for BRIVIACT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1452524 16C1001 France   Start Trial PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
1452524 300815 Netherlands   Start Trial PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
1265862 PA2016013,C1265862 Lithuania   Start Trial PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Harvard Business School
Colorcon
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.